Bristol Myers' (BMY) Opdivo Gets EC Nod for Label Expansion
Bristol Myers (BMY) obtains approval in the EU for Opdivo for the adjuvant treatment of adults and adolescents with stage IIB or IIC melanoma who have undergone complete resection.
Bristol Myers (BMY) Announces Positive Updated NSCLC Data
Bristol Myers' (BMY) repotrectinib shows durable efficacy benefits in patients with locally advanced or metastatic ROS1-Positive non-small cell lung cancer.
Pharma stocks are typically shunned by Wall St. when people feel confident about economy: Jim Cramer
'Mad Money' host Jim Cramer talks the Pharma industry facing off against the federal government over IRA provisions.
2 Dividend Stocks to Buy Hand Over Fist
Bristol Myers Squibb's declining revenue growth won't last forever. Microsoft has a strong moat and plenty of avenues for expansion.
What pharma brands will be impacted by Medicare price negotiations
Jared Holz, Mizuho healthcare strategist, joins 'The Exchange' to discuss Medicare drug price negotiations, the M&A impact of government intervention into drug pricing, and more.
Pharma ETFs in Focus Post Q2 Earnings
Second-quarter earnings beat ratio of 86.6% and revenue beat ratio of 84.9% for the healthcare sector are impressive.
Final Trades: Bristol Myers, Toast & more
The "Halftime Report" traders give their top picks to watch for the second half.
Bristol Myers Squibb stock extends bounce after announced $4 billion accelerated buyback agreements
Shares of Bristol Myers Squibb Co. BMY, +0.76% got a 0.9% bump up in premarket trading Thursday, after the biopharmaceutical company announced $4 billion in accelerated share repurchase agreements....
Related Companies